Novartis CEO Vas Narasimhan stated that the company will not compete in the "frenzy" of the weight loss drug market dominated ...

Larry Ellison becomes world's second-richest man, dethroning Jeff Bezos as Oracle stock surges The world is obsessed with forests’ climate benefits. Here’s the problem.

Join Fox News for access to this content Plus special access to select articles and other premium content with your account - free of charge. By entering your email and pushing continue, you are ...

In 2020, author Winston Groom, whose novel ''Forrest Gump'' was made into a six-Oscar winning 1994 movie that became a soaring pop cultural ... In 2021, U.S. federal regulators approved a drug from ...

It was one of those conversations you never forget. We were discussing – of all things – the Covid injections, and I was questioning the early ‘safe and effective’ claims put forward by the pharmaceut ...

Although Lilly started consistently raising its dividend in 2015, investors should be aware of some details around the schedule of these payments. Every year since then, Lilly announced a hike to its ...

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Eli Lilly exhibits robust revenue growth, with Q2 revenue surging by 36%, driven by new products contributing nearly $3.5 billion compared to the same period last year (David Ricks, Chair and CEO).